The Central Illinois Community Clinical Oncology Program (CICCOP) brings clinical trials of high scientific validity to people living in 37 counties in Central, Southern and Northeast Illinois. The service area includes 2,262,917 people living in 20,936 square miles, 19.8 percent of the populations and 37.7 percent of the land in Illinois. The CICCOP has contributed 1931 protocol entries since it was founded in 1987. The CICCOP goal is to reduce cancer incidence, morbidity and mortality by accelerating the transfer of newly developed technology to widespread community application. The specific aims are to: 1) Successfully implement National Cancer Institute (NCI) sponsored prevention and control protocols to persons living in 37 Illinois counties. 2) Successfully implement NCI sponsored cancer treatment protocols for patients with cancer living in 37 Illinois counties. 3) Benefit the care of patients and participants by collaborating with regional physicians, nurses, certified research assistants and research bases to provide a wide range of cancer research protocols locally. 4) Maintain a consortium of quality institutions and physician investigators committed to further cancer treatment and control through research. 5) Expand access to state of the art treatment and cancer control studies to the underserved populations of our service. 6) Expand the scope of the CICCOP into other Illinois communities while guarding the highest quality of research. 7) Expand access to cancer research protocols to persons living in underserved areas in Illinois by recruiting new investigators into the CICCOP from these areas while continuing to maintain the quality and integrity of cancer treatment and control clinical trials 8) Involve a wide range of specialty and primary care physicians from the CICCOP service area in cancer control protocols. 9) Ensure quality data management services to CICCOP physician investigators, research bases and NCI. 1) Maintain and enhance quality assurances procedures, physician participation policies, pharmacy regulatory requirement and protocol selection methods. 11) Comply with NCI reporting requirements in an accurate and timely manner. A small core of highly productive oncologists, a network of certified research associates (CRAs), the Central Office and very strong hospital support enables the CICCOP to meet its obligations to the NCI and to its communities by far exceeding CCOP program minimums. Between 2000 and 2005, the CCOP projects it will average 400 credits annually from treatment, cancer control and follow-up credits.
| 1 | Diagnostic Study of EF5 Binding for the Detection of Tumor Hypoxia in Patients With Stage IIB, IIIB, or IVA Cervical Cancer | |
| 2 | Diagnostic Study of Lymphatic Mapping and Sentinel Node Identification in Patients With Stage IB1 Cervical Cancer | |
| 3 | Diagnostic Study to Correlate Histopathology, Immunochemistry, and Quantitative Radiology With Outcome in Patients With Early Stage Nonseminomatous Germ Cell Tumor of the Testis | |
| 4 | Genetic Mapping of Interactive Susceptibility Loci in Patients and Siblings with Breast, Colon, Lung, or Prostate Cancer | |
| 5 | Phase I Pilot Study of Gefitinib in Patients Age 75 and Over or Age 50 and Under With Metastatic or Unresectable Carcinoma of the Head and Neck or Non-Small Cell Lung Cancer | |
| 6 | Phase I Study of Adjuvant Intraperitoneal Carboplatin and Paclitaxel in Patients With Stage III or IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Who Had Initial Debulking Surgery | |
| 7 | Phase I Study of Amifostine and High-Dose Melphalan in Patients With Primary Systemic Amyloidosis Undergoing Autologous Peripheral Blood Stem Cell Transplantation | |
| 8 | Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer | |
| 9 | Phase I Study of EGFRvIII Peptide Vaccine With Sargramostim (GM-CSF) Versus Keyhole Limpet Hemocyanin as Adjuvant in Patients With EGFRvIII-Expressing Cancer | |
| 10 | Phase I Study of Extended Field Radiotherapy, Cisplatin, and Topotecan in Patients With Locally Advanced Cervical Cancer | |
| 11 | Phase I Study of Gemcitabine, Carboplatin or Paclitaxel, and Radiotherapy Followed By Adjuvant Gemcitabine and Carboplatin in Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer | |
| 12 | Phase I Study of Intraperitoneal (IP) Carboplatin in Combination With Intravenous (IV) Docetaxel Versus IV Paclitaxel Followed By IP Paclitaxel in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma | |
| 13 | Phase I Study of Irinotecan, Cisplatin, and Thoracic Radiotherapy in Patients With Limited Stage Small Cell Lung Cancer | |
| 14 | Phase I Study of Low-Dose Abdominal Radiotherapy and Docetaxel in Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer | |
| 15 | Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer | |
| 16 | Phase I Study of Polyglutamate Paclitaxel and Carboplatin in Patients With Chemotherapy-Na??A?ve Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Carcinoma | |
| 17 | Phase I Study of Whole Pelvic Radiotherapy and Concurrent Cisplatin and Gemcitabine in Patients With Cervical Carcinoma Limited to the Pelvis | |
| 18 | Phase I/II Study of 3-D Conformal and Intensity Modulated Radiotherapy in Patients With Stage II or III Oropharyngeal Cancer | |
| 19 | Phase I/II Study of Celecoxib and Limited-Field Radiotherapy in Intermediate-Prognosis Patients With Locally Advanced Non-Small Cell Lung Cancer | |
| 20 | Phase I/II Study of Chemotherapy Comprising Methotrexate, Rituximab, and Temozolomide Before Radiotherapy and Temozolomide After Radiotherapy in Patients With Primary Central Nervous System Lymphoma | |
| 21 | Phase I/II Study of Extended Field Radiotherapy With Concurrent Paclitaxel and Cisplatin Chemotherapy in Patients With Previously Untreated Carcinoma of the Cervix Metastatic to the Para-aortic Lymph Nodes | |
| 22 | Phase I/II Study of Radiotherapy Combined With Paclitaxel and Cisplatin in Patients With Stage IB2, IIA, IIB, IIIB, or IVA Invasive Carcinoma of the Cervix | |
| 23 | Phase I/II Study of Three-Dimensional Conformal Radiotherapy In Women With Stage I or II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection | |
| 24 | Phase II Pilot Study of Docetaxel, Cisplatin, and Fluorouracil Followed By Accelerated Fractionation/Concomitant Boost Radiotherapy and Concurrent Cisplatin in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 25 | Phase II Pilot Study of Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | |
| 26 | Phase II Pilot Study of Pre-Operative Thalidomide With Radiotherapy Alone in Patients With Low-Grade Primary Soft Tissue Sarcoma or With Radiotherapy and Doxorubicin, Ifosfamide, and Dacarbazine in Patients With High- or Intermediate-Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall | |
| 27 | Phase II Pilot Study of Rituximab and Alternating Chemotherapy Regimens in Patients With Previously Untreated Mantle Cell Lymphoma | |
| 28 | Phase II Pilot Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | |
| 29 | Phase II Pilot Study of Trastuzumab (Herceptin), Docetaxel, and Vinorelbine With Filgrastim (G-CSF) Support in Women With HER2-Positive Stage IV Breast Cancer | |
| 30 | Phase II Randomized Study of Adjuvant Cetuximab and Chemoradiotherapy Comprising Cisplatin Versus Docetaxel in Patients With Resected Stage III or IV Advanced Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck | |
| 31 | Phase II Randomized Study of Anastrozole and Gefitinib Versus Fulvestrant and Gefitinib in Postmenopausal Women With Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer | |
| 32 | Phase II Randomized Study of BAY 43-9006 in Patients With Refractory Non-Small Cell Lung Cancer | |
| 33 | Phase II Randomized Study of Captopril Versus Observation in Patients With Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, or Limited Stage Small Cell Lung Cancer Previously Treated With Radiotherapy With or Without Chemotherapy | |
| 34 | Phase II Randomized Study of Celecoxib in Patients With Cervical Intraepithelial Neoplasia 3 | |
| 35 | Phase II Randomized Study of Celecoxib in Premenopausal Women at High Risk for Developing Breast Cancer | |
| 36 | Phase II Randomized Study of Cisplatin, Paclitaxel, and Concurrent Radiotherapy With or Without Fluorouracil in Patients With Previously Untreated Carcinoma of the Esophagus or Gastroesophageal Junction | |
| 37 | Phase II Randomized Study of Concurrent Versus Sequential Paclitaxel, Carboplatin, and Cetuximab in Patients With Selected Stage IIIB or Stage IV Non-Small Cell Lung Cancer | |
| 38 | Phase II Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab With or Without Epratuzumab in Patients Age 60 and Over With Previously Untreated Stage III or IV or Bulky Stage II Diffuse Large B-Cell Non-Hodgkin's Lymphoma | |
| 39 | Phase II Randomized Study of Gemcitabine and Radiotherapy Versus Gemcitabine, Fluorouracil, and Cisplatin Followed By Radiotherapy and Fluorouracil in Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Pancreas | |
| 40 | Phase II Randomized Study of Imatinib Mesylate at Standard Versus Increased Dose Alone Versus Imatinib Mesylate and Cytarabine Versus Imatinib Mesylate and PEG-Interferon alfa-2a in Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia | |
| 41 | Phase II Randomized Study of Induction Paclitaxel, Cisplatin, and Radiotherapy Versus Fluorouracil, Cisplatin, and Radiotherapy Followed By Consolidation Chemoradiotherapy or Radical Cystectomy and Adjuvant Gemcitabine, Paclitaxel, and Cisplatin in Patients With Operable Stage II or III Bladder Cancer | |
| 42 | Phase II Randomized Study of Irinotecan and Docetaxel With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Pancreas | |
| 43 | Phase II Randomized Study of Multi-Epitope Vaccination With Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Patients With Metastatic Melanoma | |
| 44 | Phase II Randomized Study of Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer Undergoing Surgical Resection | |
| 45 | Phase II Randomized Study of Radiotherapy With Pre- and Post-Operative Cisplatin Plus Paclitaxel Versus Cisplatin Plus Irinotecan in Patients With Operable Adenocarcinoma of the Esophagus or Gastroesophageal Junction | |
| 46 | Phase II Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma | |
| 47 | Phase II Randomized Study of SGN-00101 in Patients With Grade III Cervical Intraepithelial Neoplasia | |
| 48 | Phase II Randomized Study of Topotecan, Cisplatin, and Etoposide and Irinotecan, Cisplatin, and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer | |
| 49 | Phase II Study of Bortezomib in Patients With Hepatocellular Carcinoma | |
| 50 | Phase II Study of Rituximab and CHOP Chemotherapy Comprising Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Yttrium Y 90 Ibritumomab Tiuxetan (Yttrium Y 90 Zevalin??A?) in Patients With Previously Untreated Mantle Cell Lymphoma | |
| 51 | Phase II Study of 3-AP (Triapine) and Gemcitabine as Second-Line Treatment in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer | |
| 52 | Phase II Study of 3-AP and Cisplatin in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | |
| 53 | Phase II Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Docetaxel After Complete Resection in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 54 | Phase II Study of Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) and Peripheral Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia | |
| 55 | Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation With Pre-Conditioning Low-Dose Total Body Irradiation and Fludarabine Followed By Mycophenolate Mofetil and Cyclosporine in Elderly Patients With Acute Myeloid Leukemia in First Complete Remission | |
| 56 | Phase II Study of Amifostine and High-Dose Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma | |
| 57 | Phase II Study of Arsenic Trioxide in Men With Refractory Testicular or Extragonadal Germ Cell Malignancies | |
| 58 | Phase II Study of Atrasentan in Patients With Locally Recurrent or Metastatic Renal Cell Carcinoma | |
| 59 | Phase II Study of Bevacizumab in Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | |
| 60 | Phase II Study of Bevacizumab in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix | |
| 61 | Phase II Study of Bevacizumab in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma | |
| 62 | Phase II Study of Bortezomib Followed By the Addition of Doxorubicin at Disease Progression in Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma of the Head and Neck | |
| 63 | Phase II Study of Bortezomib in Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma | |
| 64 | Phase II Study of Bortezomib in Patients With Persistent or Recurrent Platinum-Sensitive Ovarian Epithelial or Primary Peritoneal Carcinoma | |
| 65 | Phase II Study of Bortezomib in Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Therapy | |
| 66 | Phase II Study of Capecitabine and Tipifarnib in Women With Taxane-Resistant Metastatic Breast Cancer | |
| 67 | Phase II Study of Capecitabine in Elderly Patients With Unresectable Metastatic or Recurrent Colorectal Cancer | |
| 68 | Phase II Study of Capecitabine in Patients With Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix | |
| 69 | Phase II Study of Carboplatin and Paclitaxel in Patients With Advanced Thymoma or Thymic Carcinoma | |
| 70 | Phase II Study of Cetuximab and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Epithelial or Primary Peritoneal Cancer | |
| 71 | Phase II Study of Cetuximab, Paclitaxel, Carboplatin, and Radiotherapy in Patients With Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer | |
| 72 | Phase II Study of Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases | |
| 73 | Phase II Study of Cisplatin and Etoposide Combined With Accelerated High-Dose Thoracic Radiotherapy in Patients With Limited Stage Small Cell Lung Cancer | |
| 74 | Phase II Study of Cisplatin, Etoposide, and Bevacizumab in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer | |
| 75 | Phase II Study of Complete Surgical Resection in Patients With Stage IV Melanoma | |
| 76 | Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma | |
| 77 | Phase II Study of Cyclosporine in Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma | |
| 78 | Phase II Study of Dalteparin and Conventional Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme | |
| 79 | Phase II Study of Docetaxel in Elderly Women With Metastatic Breast Cancer | |
| 80 | Phase II Study of Docetaxel in Patients With Locally Advanced or Metastatic Epidermoid Carcinoma of the Penis | |
| 81 | Phase II Study of Docetaxel in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix | |
| 82 | Phase II Study of Docetaxel in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| 83 | Phase II Study of Doxorubicin HCl Liposome and Docetaxel With or Without Trastuzumab (Herceptin??A?A?) in Women With Metastatic Breast Cancer | |
| 84 | Phase II Study of Doxorubicin and Gemcitabine in Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Cancer With Sarcomatoid Features | |
| 85 | Phase II Study of Early Estramustine, Etoposide, and Paclitaxel With Combined Androgen Blockade Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate | |
| 86 | Phase II Study of Erlotinib in Patients With Advanced Primary Non-Small Cell Lung Cancer and a Zubrod Performance Status of 2 | |
| 87 | Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | |
| 88 | Phase II Study of Erlotinib in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix | |
| 89 | Phase II Study of Erlotinib in Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor | |
| 90 | Phase II Study of FR901228 in Patients With Advanced Transitional Cell Carcinoma of the Urothelium That Has Progressed After Prior Chemotherapy | |
| 91 | Phase II Study of FR901228 in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer | |
| 92 | Phase II Study of GVAX Lung Cancer Vaccine in Patients With Selected Stage IIIB or Stage IV Bronchoalveolar Carcinoma | |
| 93 | Phase II Study of Gefitinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | |
| 94 | Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer | |
| 95 | Phase II Study of Gemcitabine and Paclitaxel in Patients With Advanced or Recurrent Urothelial Cancer | |
| 96 | Phase II Study of Gemcitabine, Carboplatin, and Bortezomib in Patients With Chemotherapy-Na??A?ve Advanced or Recurrent Non-Small Cell Lung Cancer | |
| 97 | Phase II Study of Gemtuzumab Ozogamicin and Cytarabine in Patients With Relapsed Acute Myeloid Leukemia | |
| 98 | Phase II Study of High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Multiple Myeloma or Primary Systemic Amyloidosis | |
| 99 | Phase II Study of High-Dose Methotrexate and Leucovorin Calcium Followed By Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme | |
| 100 | Phase II Study of Hydroxyurea in Patients With Unresectable Benign Meningioma | |
| 101 | Phase II Study of ICI 182780 in Patients With Recurrent or Metastatic Endometrial Cancer | |
| 102 | Phase II Study of Imatinib Mesylate and Capecitabine in Women With Progressive Stage IV Adenocarcinoma of the Breast | |
| 103 | Phase II Study of Imatinib Mesylate in Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP | |
| 104 | Phase II Study of Imatinib Mesylate in Patients With Metastatic or Unresectable Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) | |
| 105 | Phase II Study of Imatinib Mesylate in Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Carcinoma | |
| 106 | Phase II Study of Imatinib Mesylate in Patients With Platinum- and Taxane-Refractory Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer | |
| 107 | Phase II Study of Imatinib Mesylate in Patients With Recurrent or Persistent Uterine Carcinosarcoma | |
| 108 | Phase II Study of Induction Tirapazamine, Cisplatin, and Etoposide With Concurrent Thoracic Radiotherapy Followed By Consolidation Cisplatin and Etoposide in Patients With Limited Stage Small Cell Lung Cancer | |
| 109 | Phase II Study of Intensity-Modulated Radiotherapy With or Without Chemotherapy in Patients With Nasopharyngeal Cancer | |
| 110 | Phase II Study of Interferon alfa, Isotretinoin, and Paclitaxel in Patients With Recurrent Small Cell Lung Cancer | |
| 111 | Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Locally Recurrent Head and Neck Cancer | |
| 112 | Phase II Study of Irinotecan in Patients With Recurrent or Refractory Advanced Transitional Cell Carcinoma of the Urothelium Previously Treated With Platinum-Based Chemotherapy | |
| 113 | Phase II Study of Irofulven in Patients With Recurrent or Persistent Platinum-Sensitive Ovarian Epithelial or Primary Peritoneal Cancer | |
| 114 | Phase II Study of Ixabepilone in Patients With Metastatic Hormone-Refractory Adenocarcinoma of the Prostate | |
| 115 | Phase II Study of Ixabepilone in Patients With Advanced Carcinoma of the Urothelium | |
| 116 | Phase II Study of Low-Dose PEG-Interferon alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor | |
| 117 | Phase II Study of Methotrexate With or Without Cyclophosphamide in Patients with Large Granular Lymphocytic Leukemia | |
| 118 | Phase II Study of Minimally Invasive Esophagectomy in Patients With High-Grade Dysplasia of the Esophagus or Stage I-III Esophageal Cancer | |
| 119 | Phase II Study of Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed By Concurrent Cisplatin and Radiotherapy in Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium | |
| 120 | Phase II Study of Neoadjuvant Erlotinib in Patients With Early-Stage Operable Non-Small Cell Lung Cancer | |
| 121 | Phase II Study of Neoadjuvant Gemcitabine, Paclitaxel, and Carboplatin Followed By Observation or Immediate Cystectomy in Patients With Stage II or III Transitional Cell Cancer of the Urothelium | |
| 122 | Phase II Study of Neoadjuvant Induction Therapy Comprising Cetuximab, Paclitaxel, and Carboplatin Followed By Chemoradiotherapy Comprising Cetuximab, Paclitaxel, Carboplatin, and Radiotherapy in Patients With Stage III or IV Operable Squamous Cell Cancer of the Head and Neck | |
| 123 | Phase II Study of Neoadjuvant Oxaliplatin, Fluorouracil, and Radiotherapy Followed By Definitive Surgical Resection in Patients With Stage II or III Squamous Cell Carcinoma or Adenocarcinoma of the Esophagus or Gastroesophageal Junction | |
| 124 | Phase II Study of Neoadjuvant Paclitaxel and Carboplatin Followed By Surgery and Adjuvant Paclitaxel and Carboplatin in Patients With Stage III or IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | |
| 125 | Phase II Study of Neoadjuvant and Adjuvant Imatinib Mesylate in Patients With Primary or Recurrent Potentially Resectable Malignant Gastrointestinal Stromal Tumor | |
| 126 | Phase II Study of Nitrocamptothecin in Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | |
| 127 | Phase II Study of Paclitaxel and Carboplatin in Patients With Locally Advanced or Metastatic Collecting Duct Renal Cell Cancer | |
| 128 | Phase II Study of Paclitaxel and Celecoxib in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | |
| 129 | Phase II Study of Paclitaxel in Patients With Ovarian Stromal Cancer | |
| 130 | Phase II Study of Paclitaxel, Cisplatin, and Doxorubicin HCl Liposome in Patients With Optimally Debulked Stage III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | |
| 131 | Phase II Study of Paclitaxel, Fluorouracil, and Cisplatin Followed By Chemoradiotherapy and Possible Surgical Salvage in Patients With Resectable Locally Advanced Carcinoma of the Esophagus or Gastroesophageal Junction | |
| 132 | Phase II Study of Pemetrexed Disodium in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | |
| 133 | Phase II Study of Pemetrexed Disodium and Gemcitabine in Patients With Advanced Cancer of the Urothelium | |
| 134 | Phase II Study of Pemetrexed Disodium in Patients With Recurrent Carcinoma of the Cervix | |
| 135 | Phase II Study of Pemetrexed Disodium in Patients With Persistent or Recurrent Endometrial Adenocarcinoma | |
| 136 | Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | |
| 137 | Phase II Study of Perifosine in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer | |
| 138 | Phase II Study of Preradiation Combination Chemotherapy in Adults with Poor-Risk Medulloblastoma, Peripheral Primitive Neuroectodermal Tumor, or Disseminated Ependymoma | |
| 139 | Phase II Study of Radiotherapy and Cisplatin Followed By Resection of Residual Disease in Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva That is Not Amenable to Standard Radical Vulvectomy | |
| 140 | Phase II Study of Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Stage I or II CD20-Positive Diffuse Large Cell Lymphoma | |
| 141 | Phase II Study of Salivary Gland Transfer Surgery Prior to Radiotherapy for the Prevention of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer | |
| 142 | Phase II Study of Salvage Cellular Immunotherapy With Donor Lymphocyte Infusions in Patients With Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation from an HLA-Matched Sibling Donor | |
| 143 | Phase II Study of Stereotactic Body Radiotherapy in Patients With Medically Inoperable Stage I or II Non-Small Cell Lung Cancer | |
| 144 | Phase II Study of Surgery and Ad5CMV-p53 Gene Followed By Cisplatin and Radiotherapy in Patients With Newly Diagnosed Resectable Stage III or IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx | |
| 145 | Phase II Study of Targeted Induction Chemotherapy Followed By Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Rectum | |
| 146 | Phase II Study of Temozolomide and Whole Brain Radiotherapy in Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer | |
| 147 | Phase II Study of Thalidomide and Dexamethasone Induction Followed By Tandem Melphalan and Peripheral Blood Stem Cell Transplantation Followed By Prednisone and Thalidomide Maintenance in Patients With Multiple Myeloma | |
| 148 | Phase II Study of Topotecan in Patients With Persistent or Recurrent Carcinoma of the Cervix | |
| 149 | Phase II Study of Trastuzumab (Herceptin??A?) in Patients With Advanced, Recurrent, or Persistent Endometrial Adenocarcinoma | |
| 150 | Phase II Study of Trastuzumab (Herceptin??A?), Ixabepilone, and Carboplatin in Patients With HER2/neu-Positive Metastatic Breast Cancer | |
| 151 | Phase II Study of a Nonmyeloablative Conditioning Regimen Followed By Allogeneic Bone Marrow Transplantation in Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma | |
| 152 | Phase II Study of a Reduced-Intensity Preparative Regimen With Allogeneic Bone Marrow Transplantation in Patients With Myelodysplastic Syndromes | |
| 153 | Phase II/III Randomized Study of Prophylactic Cranial Irradiation in Patients With Limited Stage Small Cell Lung Cancer | |
| 154 | Phase III Randomized Adjuvant Study of High-Dose Interferon alfa-2b Therapy in Patients With Stage II or III Melanoma | |
| 155 | Phase III Randomized Adjuvant Study of Radiotherapy With Hormonal Therapy Versus Radiotherapy Alone in Patients With High-Risk Stage II or III Prostate Cancer | |
| 156 | Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma | |
| 157 | Phase III Randomized Chemoprevention Study of Celecoxib in Patients With Resected Stage I Adenocarcinoma of the Colon | |
| 158 | Phase III Randomized Chemoprevention Study of Selenium in Participants With Previously Resected Stage I Non-Small Cell Lung Cancer | |
| 159 | Phase III Randomized Study of Adjuvant Androgen Deprivation Therapy With or Without Mitoxantrone and Prednisone After Radical Prostatectomy in Patients With High-Risk Adenocarcinoma of the Prostate | |
| 160 | Phase III Randomized Study of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide With or Without Celecoxib Versus Doxorubicin and Cyclophosphamide With or Without Celecoxib in Women With Node-Negative Breast Cancer | |
| 161 | Phase III Randomized Study of Adjuvant Irinotecan, Fluorouracil, and Leucovorin Calcium Versus Oxaliplatin, Fluorouracil, and Leucovorin Calcium Versus Fluorouracil and Leucovorin Calcium in Patients With Stage II or III Rectal Cancer Receiving Combined Radiotherapy and Fluorouracil Either Preoperatively or Postoperatively | |
| 162 | Phase III Randomized Study of Adjuvant Isotretinoin, Interferon alfa, and Vitamin E in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 163 | Phase III Randomized Study of Allogeneic or Autologous Stem Cell Transplantation Versus Conventional Consolidation and Maintenance Chemotherapy in Patients With Acute Lymphoblastic Leukemia in First Remission | |
| 164 | Phase III Randomized Study of Amifostine Versus No Treatment For Platinum-Induced Peripheral Neuropathy in Patients With Gynecologic Malignancies | |
| 165 | Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ of the Breast Undergoing Lumpectomy and Radiotherapy | |
| 166 | Phase III Randomized Study of Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | |
| 167 | Phase III Randomized Study of Androgen Blockade With Concurrent Chemotherapy Versus Delayed Chemotherapy in Patients With High-Risk Hormone-Naive Prostate Cancer | |
| 168 | Phase III Randomized Study of Androgen Suppression and Radiotherapy With or Without Subsequent Paclitaxel, Estramustine, and Etoposide in Patients With Localized High-Risk Prostate Cancer | |
| 169 | Phase III Randomized Study of Carboplatin With or Without Pegylated Doxorubicin HCl Liposome in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | |
| 170 | Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Low-Dose Paclitaxel in Patients With Early Stage Ovarian Carcinoma | |
| 171 | Phase III Randomized Study of Carboplatin, Paclitaxel, and Chemoradiotherapy With or Without Thalidomide in Patients With Stage III Non-Small Cell Lung Cancer | |
| 172 | Phase III Randomized Study of Cisplatin Only Versus Cisplatin Plus Topotecan Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix | |
| 173 | Phase III Randomized Study of Cisplatin and Irinotecan Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer | |
| 174 | Phase III Randomized Study of Cisplatin, Etoposide, Radiotherapy, and Docetaxel With or Without Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | |
| 175 | Phase III Randomized Study of Conventional Versus Accelerated Radiotherapy and Concurrent Cisplatin With or Without Surgical Resection in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 176 | Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Either Rituximab or Iodine I 131 Tositumomab (Monoclonal Antibody Anti-B1) in Patients With Newly Diagnosed Follicular Non-Hodgkin's Lymphoma | |
| 177 | Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Gemtuzumab Ozogamicin Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia | |
| 178 | Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Zosuquidar Trihydrochloride in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB) in Transformation, or High-Risk RAEB | |
| 179 | Phase III Randomized Study of Dexamethasone With or Without CC-5013 in Patients With Newly Diagnosed Multiple Myeloma | |
| 180 | Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck | |
| 181 | Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin) in Women With Node-Positive Breast Cancer That Overexpresses HER2 | |
| 182 | Phase III Randomized Study of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Versus Doxorubicin, Vinblastine, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone (Stanford V) With or Without Radiotherapy in Patients With Locally Extensive or Advanced Hodgkin's Lymphoma | |
| 183 | Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer | |
| 184 | Phase III Randomized Study of Epoetin alfa With or Without Dexamethasone for the Treatment of Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer | |
| 185 | Phase III Randomized Study of Fibrin Sealant to Reduce Lymphedema Incidence After Lymph Node Dissection in Patients With Vulvar Malignancies | |
| 186 | Phase III Randomized Study of Fluorouracil and Mitomycin With Concurrent Radiotherapy Versus Fluorouracil and Cisplatin With Concurrent Radiotherapy in Patients With Anal Canal Carcinoma | |
| 187 | Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin Versus Capecitabine and Oxaliplatin With or Without Bevacizumab in Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer | |
| 188 | Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer | |
| 189 | Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas | |
| 190 | Phase III Randomized Study of Gemcitabine With or Without Radiotherapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer | |
| 191 | Phase III Randomized Study of Goserelin for the Reduction of Premature Ovarian Failure in Women With Stage I-IIIA Hormone Receptor-Negative Breast Cancer Undergoing Adjuvant Chemotherapy | |
| 192 | Phase III Randomized Study of High- Versus Standard-Dose Three-Dimensional Conformal or Intensity-Modulated Radiotherapy in Patients With Stage I or II Adenocarcinoma of the Prostate | |
| 193 | Phase III Randomized Study of Induction Therapy Comprising Cytarabine and Daunorubicin With Versus Without Gemtuzumab Ozogamicin Followed By Consolidation Therapy Comprising High-Dose Cytarabine and Post-Consolidation Therapy Comprising Gemtuzumab Ozogamicin Versus No Additional Therapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia | |
| 194 | Phase III Randomized Study of Interferon alfa Versus Cisplatin, Vinblastine, and Dacarbazine Plus Interferon alfa and Interleukin-2 in Patients With High-Risk Melanoma | |
| 195 | Phase III Randomized Study of Interferon alfa-2b With or Without Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma | |
| 196 | Phase III Randomized Study of Interleukin-2 Versus Observation Only After Total Body Irradiation, High-Dose Etoposide, Cyclophosphamide, and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Adult Non-Hodgkin's Lymphoma | |
| 197 | Phase III Randomized Study of Intermittent Versus Continuous Combined Androgen-Deprivation Therapy Comprising Bicalutamide and Goserelin in Patients With Metastatic Stage IV Prostate Cancer Responsive to Such Therapy | |
| 198 | Phase III Randomized Study of Interstitial Brachytherapy With or Without External Beam Radiotherapy in Patients With Intermediate-Risk Prostate Cancer | |
| 199 | Phase III Randomized Study of Juven??A? Versus a Non-Juven??A? Supplement in the Treatment of Cachexia in Patients With Unspecified Solid Tumors or Lymphoma With No Leukemic Aspect | |
| 200 | Phase III Randomized Study of L-Glutamine For Radiotherapy-Induced Oral Mucositis in Patients With Newly Diagnosed, Previously Untreated Squamous Cell Cancer of the Oral Cavity or Oropharynx Receiving High-Dose Radiotherapy | |
| 201 | Phase III Randomized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen | |
| 202 | Phase III Randomized Study of Methotrexate Versus Dactinomycin in Patients With Low-Risk Gestational Trophoblastic Neoplasia | |
| 203 | Phase III Randomized Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Observation Alone Based on p53 Gene Status in Patients With Organ Confined Transitional Cell Carcinoma of the Bladder Who Have Undergone Radical Cystectomy and Bilateral Pelvic Lymphadenectomy | |
| 204 | Phase III Randomized Study of Octreotide in Preventing or Reducing the Severity of Chemoradiotherapy-Induced Diarrhea in Patients With Anal or Rectal Cancer | |
| 205 | Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Gemcitabine, Doxorubicin HCl Liposome, or Topotecan in Patients With Stage III or IV Ovarian Epithelial or Serous Primary Peritoneal Carcinoma | |
| 206 | Phase III Randomized Study of Paclitaxel and Cisplatin Versus Vinorelbine and Cisplatin Versus Gemcitabine and Cisplatin Versus Topotecan and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix | |
| 207 | Phase III Randomized Study of Preoperative Capecitabine and Radiotherapy Versus Fluorouracil and Radiotherapy in Patients With Resectable Rectal Cancer | |
| 208 | Phase III Randomized Study of Prolonged Infusion Gemcitabine With Versus Without Oxaliplatin Versus Standard Infusion Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer | |
| 209 | Phase III Randomized Study of Prophylactic Cranial Irradiation in Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer | |
| 210 | Phase III Randomized Study of Radical Hysterectomy and Tailored Chemoradiotherapy Versus Primary Chemoradiotherapy in Patients With Stage IB2 Carcinoma of the Cervix | |
| 211 | Phase III Randomized Study of Radiotherapy Combined With Temozolomide Versus Carmustine in Patients With Anaplastic Astrocytoma or Mixed Gliomas | |
| 212 | Phase III Randomized Study of Radiotherapy With or Without Thalidomide in Patients With Multiple Brain Metastases | |
| 213 | Phase III Randomized Study of Radiotherapy and Carmustine With or Without O6-Benzylguanine in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | |
| 214 | Phase III Randomized Study of Rituximab in Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | |
| 215 | Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprised of Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma | |
| 216 | Phase III Randomized Study of Second-Line Hormonal Therapy (Ketoconazole and Hydrocortisone) Versus Combination Chemotherapy (Docetaxel and Estramustine) in Asymptomatic Patients With Prostate Cancer and a Rising Prostate-Specific Antigen After Androgen Suppression | |
| 217 | Phase III Randomized Study of Selenium as Chemoprevention of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia | |
| 218 | Phase III Randomized Study of Standard Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Weekly Paclitaxel Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide With Filgrastim (G-CSF) Followed By Weekly Paclitaxel in Women With Inflammatory or Locally Advanced Breast Cancer | |
| 219 | Phase III Randomized Study of Surgery With or Without Preoperative Paclitaxel and Carboplatin in Patients With Stage IB, II, or Selected IIIA Non-Small Cell Lung Cancer | |
| 220 | Phase III Randomized Study of Tamoxifen Versus Thalidomide in Patients With Only a Biochemical Recurrence of Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer After First-Line Chemotherapy | |
| 221 | Phase III Randomized Study of Vaginal Hysterectomy and Bilateral Salpingo-Oophorectomy (BSO) Via Laparoscopy Versus Total Abdominal Hysterectomy and BSO Via Conventional Laparotomy Plus Pelvic and Para-Aortic Lymph Node Sampling in Patients With Stage I or IIA, Grade I-III Endometrial Cancer or Uterine Cancer | |
| 222 | Phase III Randomized Study of Whole Abdominal Radiotherapy Versus Ifosfamide and Cisplatin in Patients With Optimally Debulked Stage I-IV Carcinosarcoma of the Uterus | |
| 223 | Phase III Randomized Study of Whole Breast Radiotherapy Versus Observation With or Without Optional Tamoxifen in Women With Good-Risk Ductal Carcinoma In Situ of the Breast | |
| 224 | Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma | |
| 225 | Phase III Study of Intraoperative Lymphatic Mapping in Patients With Invasive Squamous Cell Carcinoma of the Vulva | |
| 226 | Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | |
| 227 | Pilot Study of Erlotinib in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer | |
| 228 | Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer | |
| 229 | Prospective Screening Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA 125 Screening in Participants at Increased Genetic Risk of Ovarian Cancer | |
| 230 | Randomized Pilot Study to Evaluate Educational Intervention and Behavioral Skills Training for Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer | |
| 231 | Randomized Study of Fenretinide as Chemoprevention in Patients at Increased Risk for Ovarian Cancer | |
| 232 | Randomized Study of Sildenafil for Erectile Dysfunction in Patients With Prostate Cancer Treated on RTOG-9910 | |
| 233 | Study of MN Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Neoplasia in Patients With Atypical Glandular Cells of Undetermined Significance | |
| 234 | Study of Multicolor Fluorescence Immunocytochemistry and Bright Field Immunocytochemistry for the Detection of Tumor Cells in Bone Marrow of Women With Stage I, II, or IIIA Breast Cancer Undergoing Surgery | |
| 235 | Study of Vaginal Length, Elasticity, Lubrication, and Sexual Function in Patients With Stage IB2 Cervical Cancer | |
E-Mail this page
Define terms on this page
View related clinical trials conducted by this group